Munich - Delayed Quote EUR

Celyad Oncology (1C0.MU)

0.5400

+0.0470

+(9.53%)

At close: April 17 at 8:02:20 AM GMT+2

Celyad Oncology Reports Full Year 2024 Financial Results and Recent Business Highlights

MONT-SAINT-GUIBERT, Belgium, April 02, 2025--Regulatory News: Celyad Oncology (Euronext: CYAD) (the "Company"), today announces its financial results for the fiscal year ended December 31, 2024, and provides a business update.

Business Wire 16 days ago

CLYYF
Celyad Oncology announces the publication of the preclinical and clinical data of CYAD-211 providing proof-of-concept of its miRNA-based shRNA platform

MONT-SAINT-GUIBERT, Belgium, February 18, 2025--Regulatory News: Celyad Oncology (Euronext: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (the "Company"), today announces the publication of the preclinical data of the non-gene edited allogeneic CYAD-211 and clinical data from the Phase I IMMUNICY-1 clinical study which evaluated CYAD-211 in relapsed or refractory (r/r) multiple myeloma (MM) patients. The findings were published in the International Journal of Molecular Science (IJMS).

Business Wire last month

CLYYF
Celyad Oncology to Present at the 2024 SITC Annual Meeting

MONT-SAINT-GUIBERT, Belgium, October 07, 2024--Regulatory News: Celyad Oncology (Euronext: CYAD) (the "Company"), today announces two poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held in Houston, November 6-10, 2024.

Business Wire 6 months ago

CLYYF
Celyad Oncology Announces Appointment of Matt Kane as Chief Executive Officer

MONT-SAINT-GUIBERT, Belgium, September 16, 2024--Regulatory News: Celyad Oncology (Euronext: CYAD) (the "Company" or "Celyad") is pleased to announce Matt Kane as its new Chief Executive Officer (CEO), effective as of October 1st, 2024.

Business Wire 6 months ago

CLYYF
Celyad Oncology Reports First Half Year 2024 Financial Results and Recent Business Highlights

MONT-SAINT-GUIBERT, Belgium, September 13, 2024--Regulatory News: Celyad Oncology (Euronext: CYAD) (the "Company"), today announces its financial results for the first half year 2024 ended June 30, 2024, and provides a business update.

Business Wire 7 months ago

CLYYF

Performance Overview

Return	1C0.MU	BEL 20 (^BFX)
YTD	-24.26%	-0.67%
1-Year	+49.17%	+10.62%
3-Year	-74.22%	-0.44%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Celyad Oncology (1C0.MU)

Celyad Oncology Reports Full Year 2024 Financial Results and Recent Business Highlights

Celyad Oncology announces the publication of the preclinical and clinical data of CYAD-211 providing proof-of-concept of its miRNA-based shRNA platform

Celyad Oncology to Present at the 2024 SITC Annual Meeting

Celyad Oncology Announces Appointment of Matt Kane as Chief Executive Officer

Celyad Oncology Reports First Half Year 2024 Financial Results and Recent Business Highlights

Performance Overview